比卡鲁胺对T3期以上去势前列腺癌患者血清PCA3、CgA的影响

The effects of bicalutamide combined with Castration Therapy or Orchiectomy on serum PCA3 and Cg A in patients with T3 and T4 stage prostate cancer

目的探究比卡鲁胺联合药物或手术去势治疗对T3期以上前列腺癌患者血清PCA3、CgA的影响。方法将我院2014年9月-2016年9月收治的116例T3期以上前列腺癌患者按随机数字表法分为观察组和对照组,每组58例。对照组采用药物或手术去势治疗,观察组在对照组基础上联合比卡鲁胺进行治疗。结果观察组治疗效果高于对照组(P<0.05);观察组生活质量评分明显优于对照组(P<0.05);观察组PCA3、CgA水平明显低于对照组。结论采用比卡鲁胺联合药物或手术去势治疗T3期以上前列腺癌更能降低血清PCA3、CgA水平,改善患者临床症状,提高生活质量。

Objective To explore the effect of bicalutamide combined with Castration Therapy on serum PCA3 and CgA in patients with T3 and T4 stage prostate cancer. Methods A total of 116 patients with r T3 and T4 stage prostate cancer who were admitted to our hospital from September 2014 to September 2016 were randomly divided into observation group and control group with 58 cases in each group. The control group was treated with Castration Therapy or Orchiectomy and the observation group was treated with bicalutamide on the basis of the control group. Results The therapeutic effect of the observation group was higher than that of the control group (P <0.05). The quality of life score in the observation group was significantly better than that in the control group (P <0.05). The PCA3 and CgA levels in the observation group were significantly lower than those in the control group. Conclusion The use of bicalutamide combined with Castration Therapy or Orchiectomy for T3 and T4 stage prostate cancer can reduce serum PCA3, CgA levels, improve clinical symptoms, and improve quality of life.